Psivida wins technology award

By Melissa Trudinger
Thursday, 15 July, 2004

Nanotechnology company Psivida (ASX: PSD) has had its research applying its BioSilicon technology to drug delivery, diagnostics, orthopaedics and tissue engineering recognised with a 2004 Excellence in Research Award from US consulting group Frost & Sullivan.

Frost & Sullivan announced the award in a recently released study focusing on nanomedicine.

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Content from other channels on our network

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Cybersecurity and digitalisation for Zimbabwe platinum mine

ENEOS opens Direct MCH large‍-‍scale demonstration plant in Brisbane

ARENA funds manufacturing of solar construction robots

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care

Rapid-response discharge model targets bed block

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure

Epson MD serves meals for CEO CookOff

AI solar smart bins to end Vic fixed-route rubbish runs